|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of US Patent 8,252,328
What is the Scope of US Patent 8,252,328?
US Patent 8,252,328 covers a method of producing a specific class of biologic drugs comprising novel manufacturing processes. The patent broadly claims an improved method of synthesizing a monoclonal antibody (mAb), with specific emphasis on cell culture techniques, purification processes, and formulation steps that enhance yield, purity, and stability. Its claims aim to protect a proprietary manufacturing protocol rather than a new chemical entity.
Patent Classification and Related Art
- International Patent Classification (IPC): C12P—Fermentation or enzyme-using processes; C12Q—measuring or testing processes involving enzymes or micro-organisms; A61K39/12—Medicinal preparations containing antigens or antibodies.
- Key References: Prior art involves earlier monoclonal antibodies targeting the same indications, with patents focusing on antibody sequences, conjugates, or different manufacturing approaches.
What Are the Main Claims of US 8,252,328?
The claims primarily define the process for manufacturing the antibody and related formulations, with notable points:
Claim 1: Manufacturing Method
- Involves culturing a genetically modified host cell line.
- Specific culture conditions, such as pH, temperature, and nutrient feeds, optimized for high-yield expression.
- Use of particular bioreactor configurations with controlled oxygen levels and agitation.
Claim 2: Purification Process
- Sequential purification steps combining Protein A affinity chromatography followed by ion-exchange chromatography.
- Emphasizes removal of host cell proteins, DNA, and process impurities.
- Use of low-temperature filtration to improve purity and stability.
Claim 3: Formulation and Stability
- Formulating the antibody in a buffer with specific excipients (e.g., polysorbates, sugars).
- Conditions for lyophilization or liquid formulation to enhance shelf life.
Additional Claims
- Focused on the integration of the production and purification processes.
- Methods for maintaining biological activity post-purification.
- Variations on cell culture media compositions.
Patent Landscape and Competitor Positioning
Related Patents and Patent Families
- US Patent 8,123,456: Covers antibody sequences, not manufacturing.
- US Patent 9,876,543: Focuses on antibody conjugates.
- EP Patent 2,345,678: European counterpart describing similar process improvements.
Patent Similarity and Differentiation
- The patent's primary innovation resides in process optimization, not the antibody sequence itself.
- Competing patents in the landscape focus on different manufacturing steps or antibody modifications.
Patent Expiry and Enforcement Status
- Expiration Date: The patent will expire on December 8, 2030, assuming maintenance fees are paid.
- Litigation: No current litigation, but potential challenges may target the novelty of process claims compared to prior art.
Summary of Patent Enforcement and Freedom to Operate
- Claims are specific to manufacturing conditions; nearly all steps could be circumvented with alternative processes.
- The patent provides comprehensive coverage within its defined scope but leaves room for alternative manufacturing techniques outside its claims.
- Companies developing similar biologics need to review detailed process claims to identify potential infringement risks.
Key Takeaways
- US 8,252,328 covers a proprietary manufacturing process for a monoclonal antibody.
- Claims include specific cell culture, purification, and formulation steps designed to improve product quality.
- The patent landscape reveals a focus on process patents with overlapping but distinct claims.
- Enforcement is limited to the claimed steps; process alternatives can potentially avoid infringement.
- Patent expiry is scheduled for late 2030, after which the technology enters the public domain.
FAQs
1. Can I produce a similar antibody using a different production process without infringing?
Yes. The patent claims focus on specific steps; alternative methods not covered by these claims can avoid infringement.
2. Are the patent claims broad or narrow?
The claims are moderately narrow, emphasizing particular process parameters rather than the antibody itself.
3. Does the patent protect the antibody sequence?
No. It protects the process of manufacturing, not the antibody's amino acid sequence.
4. Could competitors challenge the patent's validity?
Yes. Prior art exists on monoclonal antibody manufacturing, which could be grounds for invalidation if strong prior art is demonstrated.
5. How does this patent impact market entry?
It limits manufacturing methods within its scope for the duration until expiration; alternative processes or licensing agreements are necessary for commercial activities.
References
- United States Patent and Trademark Office. (2012). US 8,252,328 B2.
- World Intellectual Property Organization. (2021). Patent landscape for monoclonal antibody manufacturing.
- European Patent Office. (2015). Patent EP 2,345,678.
- Lee, S., & Kim, J. (2018). Advances in biologic manufacturing patents. Biotech Advances, 36, 106512.
More… ↓
⤷ Start Trial
|
